It is obvious that ABBV's HCV US marketing was a total failure. Its desire to peddle an inferior product at lower prices just did not work. Even ABBV HCV GT1b sale was compromised by their desire to increase GT1a market share.
Surprisingly, ABBV's HCV EU and Japan sale does very well leaving a hope that the Next-Gen (if successful) will start on a sound foundation Then both Merck and GILD will have serious erosion of their worldwide HCV starting in mid 2017. GT3 is the key to ABBV HCV future.
As for GILD, their decision to stop further HCV pipeline development was a big mistake! Well, GILD never was an in-house pipeline development superpower.
Market Data 
Markets 
AI
